Kornimate/medical-research-clean huggingface dataset:
establishment of a cohort for continuous coronary artery cta scanning and predictive analysis of plaque progression

Conditions: CAD - Coronary Artery Disease

Summary: this research develops risk prediction models for coronary artery stenosis and vulnerable plaques. the coronary artery stenosis model aims to predict stenosis using multimodal deep learning by integrating text, structured numerical data, and imaging features, focusing on metrics like maximum and cumulative stenosis. the vulnerable plaque model seeks to identify early formation indicators, allowing for timely interventions to prevent plaque rupture, using similar data integration techniques. additionally, a decision support system is created, comprising a patient database, risk prediction models, and a high-risk alert module. this system facilitates real-time notifications to healthcare providers when risk thresholds are exceeded, enabling personalized treatment planning and improved patient outcomes.


Eligibility criteria:
inclusion criteria: patients who have undergone multiple consecutive ccta examinations. exclusion criteria: patients who have undergone only a single ccta examination. patients whose ccta image quality is poor and cannot be analyzed.
influence of expiration lente prolongée on gastro-oesophageal reflux

Conditions: Gastro-esophageal Reflux

Summary: the purpose of this study is to determine whether a specific airway clearance technique, l'expiration lente prolongée (elpr), induces or aggravates gastro-oesophageal reflux in infants under the age of one year. infants referred to hospital for a multichannel intraluminal impedance ph (ph-mii) monitoring are included in this study. participation is only possible after signing the informal consent by one of the parents.


Eligibility criteria:
inclusion criteria: * infants under the age of one year and on suspicion of gor who were referred for 24h impedance-ph monitoring are included in this study. exclusion criteria: * prematurity (gestational age less than 37 weeks), * the use of anti-reflux medication and reflux surgery (nissen fundoplication)
psychometric properties of pain scale in low back pain

Conditions: Chronic Low Back Pain

Summary: the aim of this study was to examine the turkish validity of the pain behavior scale in a population with chronic non-specific low back pain and to examine both intra-rater and inter-rater reliability. in addition, since this test package includes a series of functional activities, it is aimed to assess pain behaviors during functional movement in this population and to verify the test-retest reliability of physical performance tests.

to assess the extent to which individuals with chronic low back pain are affected during functional task performance, the presence or absence of pain behaviors and the severity of observed pain behavior should be considered. the pain behavior scale has potential clinical application both for assessing pain behaviors during regular physical examination and for measuring the presence and severity of pain behaviors during functional movement. there is no similar assessment tool that offers all of these simultaneously. therefore, this study aimed to examine the turkish validity of the pain behavior scale in a population with chronic non-specific low back pain and to test its intra- and inter-rater reliability.

Eligibility criteria:
inclusion criteria: * non-specific low back pain for more than three months * being between the ages of 18-55 * adequate cognitive functions (reading, writing, recall, orientation, language) exclusion criteria: * presence of a serious underlying pathology (e.g. cancer, infection or cauda equina syndrome) * presence of spinal stenosis * presence of signs of radiculopathy (presence of neural symptoms such as pain radiating to the lower extremities, weakness, numbness and tingling sensation) * presence of fracture or surgical history in the relevant area * presence of rheumatic disease history * presence of pregnancy

Keywords: psychometric properties pain behavior scale
identification of genes associated with lung disease in patients with rheumatoid arthritis

Conditions: Healthy; Pulmonary Fibrosis; Rheumatoid Arthritis

Summary: pulmonary fibrosis (pf) is a condition in which the lungs of a patient become scarred and fibrous. it has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (ra). the cause of the pulmonary fibrosis in patients with ra is unknown. data gathered from previous research studies suggest that genetics may play a role in the development of pf in patients with rheumatoid arthritis. however, the actual genetic factors involved in the disease process have not been identified. the goal of this study is to identify the genetic markers in patients with pulmonary fibrosis and rheumatoid arthritis.

pulmonary fibrosis that develops within a subpopulation of patients with rheumatoid arthritis is a disorder of unknown etiology. although previous reports suggest that some individuals with rheumatoid arthritis have a genetic predisposition to the development of fibrotic lung disease, genetic factors have not been clearly identified. it is the intent of this clinical protocol to identify genetic polymorphisms in individuals with pulmonary fibrosis and rheumatoid arthritis.

Eligibility criteria:
* inclusion criteria: individuals 21 years of age or older with any of the following: ra (based on 1987 american college of rheumatology revised criteria for the classification of ra) with pf (biopsy-proven), or ra-only, or biopsy-proven idiopathic pf-only, or healthy research volunteers. exclusion criteria: individuals with any of the following: inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium). chronic pulmonary disorders other than pulmonary fibrosis. other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease). non-rheumatoid arthritis. viral infections associated with pf (e.g., hepatitis b, hepatitis c, human immunodeficiency virus). pregnancy.

Keywords: interstitial lung disease inherited disease genetic markers alpha 1 protease inhibitor dna mutations rheumatoid arthritis pulmonary fibrosis normal volunteer
relation of glucose and acute pancreatitis

Conditions: Acute Pancreatitis

Summary: acute pancreatitis (ap) is an acute inflammatory disease of the pancreas which can lead to a systemic inflammatory response syndrome with significant morbidity and mortality in 20% of patients. part of endocrine function of pancreas would be affected in ap. stress hyperglycemia would explode at acute phase. so the investigators decide to follow up and observe 200 cases of patients with acute pancreatitis, determining of blood sugar, blood amylase, hemoglobin and glycosylated hemoglobin level. at last, using roc curve method to identify the die cutting between blood glucose level and acute pancreatitis, and makes analysis of the diagnostic value.

acute pancreatitis (ap) is an acute inflammatory disease of the pancreas which can lead to a systemic inflammatory response syndrome with significant morbidity and mortality in 20% of patients. part of endocrine function of pancreas would be affected in ap. stress hyperglycemia would explode at acute phase. there are two reasons. one is because that sympathetic hyperactivity makes glucagon elevated. secondary, microcirculation disorder makes pancreas edema, ischemia and necrosis, affecting secretion and excretion of insulin. in severe acute pancreatitis, there may be ketoacidosis. many scoring systems for predicting prognosis of severe acute pancreatitis also contains glucose values, such as the ranson scoring system and the glascow scoring system. on the other hand, type 2 diabetes has become a global pandemic disease. most of patients of type 2 diabetes are obese, who easily complicated gallstone disease and hypertriglyceridemia. all of above could be the risk factors for acute pancreatitis. our initial small sample research also suggests undiagnosed diabetes patients whose glucose value elevated is significantly worse than the known diabetic patients. therefore, the investigators believe that glucose directly affects the prognosis of ap. so the investigators decide to follow up and observe 1000 cases of patients with acute pancreatitis, determining of blood sugar, blood amylase, hemoglobin and glycosylated hemoglobin level. at last, using roc curve method to identify the die cutting between blood glucose level and acute pancreatitis, and makes analysis of the diagnostic value.

Eligibility criteria:
inclusion criteria: patients that newly diagnosed as acute pancreatitis. exclusion criteria: exclude other acute abdomen, such as peptic ulcer with perforation, mesenteric arterial embolism or ruptured ectopic pregnancy.

Keywords: glucose prognosis glycated hemoglobin
evaluation of refractive outcomes in patients undergoing presbyond using the mel90 excimer laser

Conditions: Presbyopia

Summary: the goal of this clinical trial is to collect information on vision outcomes in people aged 45 to 65 who have difficulty seeing clearly at near distances due to aging (a condition called presbyopia). all participants will receive the same treatment: laser eye surgery with the presbyond method using the mel 90 excimer laser. the main questions this study aims to answer are: * how well do patients see at distance, intermediate, and near after treatment? * how satisfied are patients with their vision after surgery? participants will: * attend seven visits over six months (before surgery and after surgery at 1 day, 1 week, 1 month, 3 months, and 6 months) * undergo laser eye surgery with presbyond * complete vision tests and questionnaires about their experience there is no comparison group in this study.


Eligibility criteria:
inclusion criteria: 1. subjects between 45 and 65 years old 2. scheduled to undergo bilateral lasik treatment with presbyond 3. preoperative corrected distance visual acuity of 20/20 snellen or better in each eye 4. normal corneal topography in each eye 5. discontinue use of contact lenses at least 1 month for hard contacts and 1 week for soft lenses prior to the preoperative examination 6. residual stromal thickness ≥250 microns in each eye 7. availability, willingness, to comply with examination follow up visits 8. signed informed consent and data protection documents 9. patients successfully passed the tolerance test exclusion criteria: 1. mixed astigmatism in any eye 2. irregular corneal astigmatism in any eye 3. clinically significant ocular surface disease in any eye 4. history of ocular surgery, ocular pathology, or other significant ocular findings that, in the investigator's opinion, may increase the patient's risk for corneal refractive surgery or affect potential visual outcomes in each eye 5. prior corneal refractive surgery (smile, lasik, lasek, rk, prk, etc,) in each eye 6. amblyopia, strabismus, nystagmus, forme fruste keratoconus in any eye 7. clinically significant pupil abnormalities in any eye 8. use of systemic or ocular medications that may affect visual outcomes 9. systemic pathology that may affect the results of the study 10. pregnancy or being treated for conditions associated with hormonal fluctuation 11. participation in another clinical trial in the last 30 days
rtms for depressive, positive and negative symptoms, and physiological indices of schizophrenia patients

Conditions: Schizophrenia and Related Disorders

Summary: around 40% of schizophrenia patients present depressive symptoms, which are associated with elevated suicide and violence risk and poor prognosis and quality of life. recent meta-analysis showed the effect size of antidepressants for depressive symptoms of schizophrenia patients was as low as 0.25, so new therapeutic approach is warranted. repetitive transcranial magnetic stimulation (rtms) is a non-invasive, anesthesia-free brain stimulation therapy for treatment refractory depression. currently, rtms is classified as high-frequency stimulation (\>5hz, usually 10hz or 20hz) and low-frequency inhibition (usually 1hz). intermittent theta burst stimulation (itbs) is a new variant of rtms, with stimulation frequency as high as 50hz. compared with high-frequency rtms, itbs has similar therapeutic effect and shorter stimulation duration. up to now, studies exploring treatment effect of rtms or itbs for schizophrenia patients mainly focused on negative symptoms rather than depressive symptoms. therefore, this study aims to explore treatment effect of rtms or itbs of depressive symptoms, negative symptoms, cognitive function and physiological indices for schizophrenia patients.


Eligibility criteria:
inclusion criteria: * age ≥ 20 years * able to give informed consent * diagnosed with schizophrenia or schizoaffective disorder according to dsm-5 * has a score ≥ 7 on calgary depression scale for schizophrenia * the principal psychotropic agents are not changed within one month of the first session of rtms exclusion criteria: * dsm-5 defined substance use disorder (excluding tobacco) in the past 3 months * have clinically relevant cognitive impairment (e.g., delirium, intellectual disability or mmse \< 15) * with electronic and/or magnetic implants (e.g. pacemaker, implantable cardioverter defibrillator \[icd\], cerebral shunts, cochlear implant, etc.) * with metallic or mechanic fragments (e.g., screws, plates, stents, clips, etc.) * pregnant, or has a pregnancy plan within 3 months * with any known or history of neurological conditions including cerebral vascular accidents, epilepsy (or epileptiform waves detected by eeg prior to the first session of rtms), brain tumor or space occupying lesion * received rtms or itbs treatment within 3 months * has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results

Keywords: schizophrenia repetitive transcranial magnetic stimulation
the effects of an nr2b nmda antagonist, cp-101,606, in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: to determine the effects of the nmda antagonist, cp-101,606, in subjects with parkinson's disease


Eligibility criteria:
inclusion criteria: * 30- 80-year-old pd patients (uk parkinson's disease brain bank criteria) with a hoehn \& yahr stage score of 2-5 in the "off" state. exclusion criteria: * subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
precision psychiatry continuity clinic project

Conditions: Depressive Disorders; Depressive Symptoms; Anxiety Disorders and Symptoms; Psychological Distress; Mood Disorders

Summary: this is a demonstration project focused on translating neuroscience insights into clinical practice. the researchers will evaluate how neuroscience assessments may be applied in the clinical setting to help inform care decisions. the aim of the study is to undertake a pragmatic pilot trial to assess whether the inclusion of structured feedback from neuroscience assessments has an effect on improving patient outcomes. the study will investigate how neuroscience assessments can be integrated into and improve clinical care. the impact of sharing information and conclusions from these assessments with psychiatric providers will be explored. outcomes will include symptoms, social/occupational function and qualify of life.


Eligibility criteria:
inclusion criteria: * 18+ years of age * fluent and literate in english, and able to understand task instructions * fmri scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures) * must be referred for treatment at the stanford department of psychiatry continuity clinic exclusion criteria: * presence of suicidal ideations representing imminent risk * general medical condition, disease or neurological disorder that interferes with the assessments * traumatic brain injury (history of physical brain injury or blow to the head resulting in loss of consciousness greater than five minutes) and which could interfere with doing the assessments * severe impediment to vision, hearing and/or hand movement, likely to interfere with ability to complete the assessments, or are unable and/or unlikely to follow the study protocols * pregnancy * presence of acute psychosis, schizophrenia spectrum, or other psychotic disorders * concurrent participation in intervention or treatment studies
calcium metabolism in mexican american adolescents

Conditions: Osteoporosis

Summary: the purpose of this study is to identify calcium metabolism characteristics in mexican american adolescents. the investigators predict that calcium requirements to maximize bone health in this population will be lower than for white youth but higher than their current intakes.

previously significant racial and sex differences in calcium retention and kinetics in adolescents has been found. other minority groups have increased calcium absorption efficiency at low calcium intakes in contrast to white adolescents. since hispanics and specifically mexican americans will soon comprise an increasing proportion of our population. we propose to identify calcium metabolism characteristics in this group. we predict that calcium requirements to maximize bone health in this population will be lower than for white youth but higher than their current intakes. thus the specific aims of this project include: * to establish calcium requirements * to establish the relationship between calcium intake and calcium absorption * to identify the major physiological parameters(kidney, intestine, bone) that contribute to calcium retention in mexican-american adolescents during this two-phase metabolic camp participants will consume either a higher calcium diet(1100-2300mg/d) or a lower calcium diet (600-1200mg/d) during the first 3-week phase and switch to the opposite regime during the second 3-week phase, with a 2-week washout period in between. subjects will collect all excreta during both phases. calcium absorption, height, weight, and bone density will evaluated throughout the 6-week period of the study.

Eligibility criteria:
inclusion criteria: * normal, healthy adolescents of mexican american descent * mexican american boys age 13-15 * mexican american girls age 12-14 exclusion criteria: * malabsorptive disorders * anemia * smoking * history of medications known to affect calcium metabolism * body weight outside 85-120% of ideal body weight for height * regular consumption of illegal drugs * contraceptive use * pregnancy

Keywords: calcium healthy mexican-american adolescents camp girls boys bone
pacing the atrium to confirm or exclude pacemaker indication in tavi

Conditions: Aortic Valve Stenosis

Summary: the current observational registry aims to evaluate in patients undergoing tavi implantation: 1. the positive and negative predictive value for ppm post tavi of wenckebach phenomenona (wb) during rap during the tavi procedure, 2. baseline and procedural characteristics of tavi-implantation associated with new conduction abnormalities and need for ppm implantation, 3. peri-procedural safety, in-hospital and 1-month outcomes after tavi implantation.

the persistent growth in transcatheter aortic valve implantation (tavi) calls for optimized early discharge programs to handle the increasing patient load. while access site bleeding and stroke rate have decreased with improved technologies and operators' experience, acquired conduction abnormalities necessitating prolonged rhythm-monitoring and permanent pacemaker (ppm) implantation have remained largely unchanged, and even up to 39.9% for some tavi platforms. prompt identification of patients necessitating ppm implantation leads to optimal patient care and use of resources. conversely, prompt identification of patients with low -to no- risk for ppm post tavi shortens their hospitalization and facilitates early and safe discharge. several baseline characteristics such as age, preexistent right bundle branch block (rbbb) and the use of self-expanding valves are associated with post-tavi ppm implantation, but more practical and clinically more relevant parameters are needed with high negative and positive predictive values that could support clinical decision-making. en passant rapid atrial pacing (rap) immediately following tavi has recently been reported to be a valuable tool in ppm risk stratification. the absence of wenckebach phenomena post implantation at rap up to 120/' has a negative predictive value for ppm of 98.7%.2 first use of rap in routine practice at az sint jan brugge can confirm these first results (unpublished data). this technique improves our clinical assessment and identification of low-risk patients for ppm suitable for safe early discharge, as well as high-risk patients requiring further rhythm monitoring and eventual ppm implantation. the current observational registry aims to evaluate in patients undergoing tavi implantation: 1. the positive and negative predictive value for ppm post tavi of wenckebach phenomenona (wb) during rap during the tavi procedure, 2. baseline and procedural characteristics of tavi-implantation associated with new conduction abnormalities and need for ppm implantation, 3. peri-procedural safety, in-hospital and 1-month outcomes after tavi implantation.

Eligibility criteria:
inclusion criteria: * all patients in sinus rhythm with tavi exclusion criteria: * patients in atrial fibrillation at the time of the implantation * patients with pre-existent pacemaker
glargine u300 hospital trial

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to find out if treatment with glargine u300 when compared to glargine u100 will result in similar sugar control in patients with type 2 diabetes (t2d), who are admitted to the hospital and then transition at home, after discharge from the hospital.

several randomized clinical trials done previously in medicine and surgical patients with t2d have shown that basal bolus regimen with glargine results in a lower mean daily blood glucose (bg) concentrations compared to the sole use of sliding scale regular insulin (ssi) and in lower rate of hospital complications. glargine u300 results in similar improvement but in lower rate of hypoglycemia than treatment with glargine u100. no previous studies; however, have compared the efficacy and safety of glargine u300 in the management of hyperglycemia and diabetes in the hospital setting. this study will determine if treatment with glargine u300 has a similar glucose control in patients with diabetes admitted to the hospital and if glargine u300 will result in lower number of low blood sugars compared to glargine u100 .

Eligibility criteria:
inclusion criteria: * males or females between \> 18 years admitted to a general medicine or surgical service. * known histories of t2d treated with either diet alone, oral monotherapy, any combination of oral antidiabetic agents, short-acting glp1-ra (exenatide, liraglutide) or insulin therapy with the exception of degludec and glargine u300. * subjects must have an admission/randomization bg \> 140 mg and \< 400 mg/dl without laboratory evidence of diabetic ketoacidosis (bicarbonate \< 18 meq/l, ph \< 7.30, or positive serum or urinary ketones). exclusion criteria: * subjects with increased bg concentration, but without a known history of diabetes. * patients treated with degludec or glargine u300, or with long-acting weekly glp1-ra (weekly exenatide, dulaglutide or albiglutide). * patients with acute critical or surgical illness admitted to the icu or expected to require admission to the icu. * patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (egfr\< 30 ml/min). * mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. * female subjects who are pregnant or breast feeding at time of enrollment into the study.

Keywords: blood glucose